1.01 USD
0 (0%)
Overall SXTP gets a fundamental rating of 2 out of 10. We evaluated SXTP against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SXTP have multiple concerns. While showing a medium growth rate, SXTP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SXTP has reported negative net income.
In the past year SXTP has reported a negative cash flow from operations.
In the past 5 years SXTP always reported negative net income.
SXTP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SXTP's Return On Assets of -198.65% is on the low side compared to the rest of the industry. SXTP is outperformed by 90.10% of its industry peers.
SXTP's Return On Equity of -342.13% is on the low side compared to the rest of the industry. SXTP is outperformed by 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -198.65% | ||
| ROE | -342.13% | ||
| ROIC | N/A |
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 63.74%, SXTP is doing good in the industry, outperforming 71.88% of the companies in the same industry.
In the last couple of years the Gross Margin of SXTP has declined.
SXTP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.74% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SXTP has more shares outstanding
Compared to 1 year ago, SXTP has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -18.55, we must say that SXTP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -18.55, SXTP is doing worse than 83.85% of the companies in the same industry.
SXTP has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SXTP (0.06) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.55 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
SXTP has a Current Ratio of 2.27. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
SXTP has a Current ratio of 2.27. This is comparable to the rest of the industry: SXTP outperforms 41.15% of its industry peers.
SXTP has a Quick Ratio of 1.80. This is a normal value and indicates that SXTP is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.80, SXTP perfoms like the industry average, outperforming 42.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
SXTP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.25%, which is quite impressive.
The Revenue has grown by 168.69% in the past year. This is a very strong growth!
Measured over the past years, SXTP shows a very negative growth in Revenue. The Revenue has been decreasing by -52.49% on average per year.
EPS 1Y (TTM)61.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
Revenue 1Y (TTM)168.69%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%
3.2 Future
Based on estimates for the next years, SXTP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.73% on average per year.
The Revenue is expected to grow by 48.16% on average over the next years. This is a very strong growth
EPS Next Y94.26%
EPS Next 2Y36.27%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year94.66%
Revenue Next 2Y88.83%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SXTP's earnings are expected to grow with 25.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.27%
EPS Next 3Y25.73%
5. Dividend
5.1 Amount
No dividends for SXTP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SXTP (11/21/2025, 8:01:42 PM)
1.01
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11%
Inst Owner Change179.48%
Ins Owners1.2%
Ins Owner Change0.44%
Market Cap4.27M
Revenue(TTM)681.40K
Net Income(TTM)-8.31M
Analysts80
Price Target6.63 (556.44%)
Short Float %1.65%
Short Ratio0.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.98%
Min EPS beat(2)-27.66%
Max EPS beat(2)-16.31%
EPS beat(4)0
Avg EPS beat(4)-80.11%
Min EPS beat(4)-247.17%
Max EPS beat(4)-16.31%
EPS beat(8)1
Avg EPS beat(8)-42.74%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.66%
Min Revenue beat(2)-29.6%
Max Revenue beat(2)0.28%
Revenue beat(4)1
Avg Revenue beat(4)-19.46%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)0.28%
Revenue beat(8)1
Avg Revenue beat(8)-27.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.14%
PT rev (3m)-7.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.76 | ||
| P/tB | 1.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-17.67
EYN/A
EPS(NY)-5.47
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.23
BVpS0.57
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -198.65% | ||
| ROE | -342.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.74% | ||
| FCFM | N/A |
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 145.9% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | -18.55 |
F-Score3
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
EPS Next Y94.26%
EPS Next 2Y36.27%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)168.69%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%
Revenue Next Year94.66%
Revenue Next 2Y88.83%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%
EBIT growth 1Y13.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.33%
OCF growth 3YN/A
OCF growth 5YN/A
60 DEGREES PHARMA INC / SXTP FAQ
What is the fundamental rating for SXTP stock?
ChartMill assigns a fundamental rating of 2 / 10 to SXTP.
Can you provide the valuation status for 60 DEGREES PHARMA INC?
ChartMill assigns a valuation rating of 1 / 10 to 60 DEGREES PHARMA INC (SXTP). This can be considered as Overvalued.
What is the profitability of SXTP stock?
60 DEGREES PHARMA INC (SXTP) has a profitability rating of 1 / 10.
What is the expected EPS growth for 60 DEGREES PHARMA INC (SXTP) stock?
The Earnings per Share (EPS) of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 94.26% in the next year.